AngioDynamics Launches DuraFlow™ 2 Chronic Hemodialysis Catheter
New Offering Provides Additional Configurations, and Convenient Packaging for Inventory Control and Out-Patient Settings
Albany, NY (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, has announced the U.S. launch of the next generation DuraFlow™ 2 chronic hemodialysis catheter and the upcoming launch of the DuraFlow™ 2 VascPak® (VP) kit.
"The DuraFlow 2 chronic hemodialysis catheter is designed to improve patient outcomes by providing higher blood flow over a longer timeframe with lower recirculation rates," said Alan Panzer, Senior Vice President and General Manager for AngioDynamics. "This latest product evolution features a redesigned kit that is not only more convenient for institutions looking to better control inventories, but also expands the product's appeal to vascular access centers where 45% of all chronic dialysis catheter placements occur."
Along with the DuraMax® chronic hemodialysis catheter, AngioDynamics offers the only 48 cm chronic dialysis catheters on the market, allowing for femoral catheter placements in patients of varying sizes. The DuraFlow 2 catheter continues to provide optimal ease of insertion and sustained high flow rates. A new tough, rigid thermoplastic polyurethane luer increases durability, allowing for more secure fastening to dialysis machines.
The new streamlined VP kit, set for launch in the fiscal 2012 third quarter, is designed to meet the needs of many outpatient vascular access centers. Additionally, tray sizes for both the VP and basic kits have been reduced by approximately 30 percent, providing an ideal fit with popular automated medical supply stations and easier handling and storage.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011, and AngioDynamics' Form 10-Q for the quarterly period ended November 30, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved.